Apolipoprotein B mRNA editing catalytic polypeptide-like 3B (APOBEC3B) is expressed in tissue-specific manner. It has two zinc (Z)-coordinating deaminase domains. APOBEC3B is mapped to human chromosome 22q13.1. It belongs to cytidine deaminases family.
Synonyms: FLJ21201; PHRBNL
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: Apolipoprotein B mRNA editing catalytic polypeptide-like 3B (APOBEC3B) incorporates cytidine (C) to uridine (U) in mRNA and cytidine to thymidine mutations single stranded DNA. It interacts with core proteins of human immunodeficiency virus and hepatitis B virus and alters their genome during reverse transcription process. APOBEC3B is highly expressed in breast, lung, bladder, cervix and lung carcinomas. Uracil lesion generation by APOBEC3B is considered as major contributor of mutations in various cancers.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC